Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.

Hanan El Marroun, Vincent W V Jaddoe, James J Hudziak, Sabine J Roza, Eric A P Steegers, Albert Hofman, Frank C Verhulst, Tonya J H White, Bruno H C Stricker, Henning Tiemeier
{"title":"Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.","authors":"Hanan El Marroun,&nbsp;Vincent W V Jaddoe,&nbsp;James J Hudziak,&nbsp;Sabine J Roza,&nbsp;Eric A P Steegers,&nbsp;Albert Hofman,&nbsp;Frank C Verhulst,&nbsp;Tonya J H White,&nbsp;Bruno H C Stricker,&nbsp;Henning Tiemeier","doi":"10.1001/archgenpsychiatry.2011.2333","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed to pregnant women, but knowledge about their unintended effects on child health is scarce.</p><p><strong>Objective: </strong>To examine the effects of maternal SSRI use during pregnancy on fetal growth and birth outcomes.</p><p><strong>Design: </strong>The study was embedded in the Generation R Study, a prospective population-based study from fetal life onward.</p><p><strong>Participants: </strong>Seven thousand six hundred ninety-six pregnant women were included. Selective serotonin reuptake inhibitor use was assessed by questionnaires in each trimester and verified by pharmacy records. Using depressive symptom scores from the Brief Symptom Inventory, 7027 pregnant mothers (91.3%) had no or low depressive symptoms, 570 pregnant mothers (7.4%) had clinically relevant depressive symptoms and used no SSRIs, and 99 pregnant mothers (1.3%) used SSRIs.</p><p><strong>Main outcome measures: </strong>Fetal ultrasonography was performed in each trimester. We determined fetal body and head growth with repeated assessments of body and head size. The birth outcomes studied were preterm birth, small for gestational age, and low birth weight.</p><p><strong>Results: </strong>Fetuses from mothers with prenatal depressive symptoms showed reduced body growth (β=-4.4 g/wk; 95% CI: -6.3 to -2.4; P<.001) and head growth (β=-0.08 mm/wk; 95% CI: -0.14 to -0.03; P=.003). Mothers using SSRIs during pregnancy had fewer depressive symptoms than mothers in the clinical symptom range. Prenatal SSRI use was not associated with reduced body growth but was associated with reduced fetal head growth (β=-0.18 mm/wk; 95% CI: -0.32 to -0.07; P=.003). The SSRI-exposed children were at higher risk for preterm birth (odds ratio=2.14; 95% CI: 1.08 to 4.25; P=.03).</p><p><strong>Conclusions: </strong>Untreated maternal depression was associated with slower rates of fetal body and head growth. Pregnant mothers treated with SSRIs had fewer depressive symptoms and their fetuses had no delay in body growth but had delayed head growth and were at increased risk for preterm birth. Further research on the implications of these findings is needed.</p>","PeriodicalId":8286,"journal":{"name":"Archives of general psychiatry","volume":" ","pages":"706-14"},"PeriodicalIF":0.0000,"publicationDate":"2012-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1001/archgenpsychiatry.2011.2333","citationCount":"166","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of general psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/archgenpsychiatry.2011.2333","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 166

Abstract

Context: Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed to pregnant women, but knowledge about their unintended effects on child health is scarce.

Objective: To examine the effects of maternal SSRI use during pregnancy on fetal growth and birth outcomes.

Design: The study was embedded in the Generation R Study, a prospective population-based study from fetal life onward.

Participants: Seven thousand six hundred ninety-six pregnant women were included. Selective serotonin reuptake inhibitor use was assessed by questionnaires in each trimester and verified by pharmacy records. Using depressive symptom scores from the Brief Symptom Inventory, 7027 pregnant mothers (91.3%) had no or low depressive symptoms, 570 pregnant mothers (7.4%) had clinically relevant depressive symptoms and used no SSRIs, and 99 pregnant mothers (1.3%) used SSRIs.

Main outcome measures: Fetal ultrasonography was performed in each trimester. We determined fetal body and head growth with repeated assessments of body and head size. The birth outcomes studied were preterm birth, small for gestational age, and low birth weight.

Results: Fetuses from mothers with prenatal depressive symptoms showed reduced body growth (β=-4.4 g/wk; 95% CI: -6.3 to -2.4; P<.001) and head growth (β=-0.08 mm/wk; 95% CI: -0.14 to -0.03; P=.003). Mothers using SSRIs during pregnancy had fewer depressive symptoms than mothers in the clinical symptom range. Prenatal SSRI use was not associated with reduced body growth but was associated with reduced fetal head growth (β=-0.18 mm/wk; 95% CI: -0.32 to -0.07; P=.003). The SSRI-exposed children were at higher risk for preterm birth (odds ratio=2.14; 95% CI: 1.08 to 4.25; P=.03).

Conclusions: Untreated maternal depression was associated with slower rates of fetal body and head growth. Pregnant mothers treated with SSRIs had fewer depressive symptoms and their fetuses had no delay in body growth but had delayed head growth and were at increased risk for preterm birth. Further research on the implications of these findings is needed.

母亲使用选择性血清素再摄取抑制剂,胎儿生长和不良出生结局的风险。
背景:选择性5 -羟色胺再摄取抑制剂(SSRIs)经常被开给孕妇,但关于它们对儿童健康的意外影响的知识很少。目的:探讨妊娠期母亲使用SSRI对胎儿生长和出生结局的影响。设计:该研究嵌入R世代研究,这是一项从胎儿期开始的前瞻性人群研究。参与者:包括7,696名孕妇。选择性5 -羟色胺再摄取抑制剂的使用在每个三个月通过问卷评估和药房记录验证。使用简短症状量表的抑郁症状评分,7027名孕妇(91.3%)无抑郁症状或轻度抑郁症状,570名孕妇(7.4%)有临床相关抑郁症状且未使用SSRIs, 99名孕妇(1.3%)使用SSRIs。主要观察指标:在每个妊娠期进行胎儿超声检查。我们通过反复评估身体和头部大小来确定胎儿身体和头部的生长情况。研究的出生结局是早产、胎龄小和低出生体重。结果:有产前抑郁症状的母亲所生的胎儿身体生长减慢(β=-4.4 g/周;95% CI: -6.3 ~ -2.4;结论:未经治疗的母亲抑郁症与胎儿身体和头部生长速度较慢有关。接受SSRIs治疗的孕妇抑郁症状较少,胎儿的身体发育没有延迟,但头部发育迟缓,早产的风险增加。需要对这些发现的含义进行进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Archives of general psychiatry
Archives of general psychiatry 医学-精神病学
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信